ReviewNature reviews. Urology2013
Risk stratification in prostate cancer screening.
Review in Nature reviews. Urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03665922 (Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer), which is not on this map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Dampened Regulatory Circuitry of TEAD1/ITGA1/ITGA2 Promotes TGFβ1 Signaling to Orchestrate Prostate Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Pooled it
- Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose-response meta-analysis.Prostate cancer and prostatic diseases · 2018Pooled it
- Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2017Pooled it
- A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies.European urology · 2014Pooled it
- Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial.Cancer prevention research (Philadelphia, Pa.) · 2020Trial
- Deep Transfer Learning Links Benign Glands to Prostate Cancer Progression via Transcriptomics.Genomics, proteomics & bioinformatics · 2025Article
- Balancing Early Detection and Overtreatment in Prostate Cancer: The Emerging Role of EpihTERT.Cancers · 2025Article
- Extracellular Vesicles in Serum Carry Trop2 Protein as a Potential Molecular Indicator in Prostate Cancer.Journal of extracellular biology · 2025Article
- Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [Physical and engineering sciences in medicine · 2025Article
- Survival Outcomes for Men over 80 Years Undergoing Transrectal Ultrasound-Guided Prostate Biopsy: A Prospective Analysis.Cancers · 2024Article
- Semen sEV tRF-Based Models Increase Non-Invasive Prediction Accuracy of Clinically Significant Prostate Cancer among Patients with Moderately Altered PSA Levels.International journal of molecular sciences · 2024Article
- Integrative bioinformatics approach yields a novel gene expression risk model for prognosis and progression prediction in prostate cancer.Journal of cellular and molecular medicine · 2024Article
- Artificial intelligence unravels interpretable malignancy grades of prostate cancer on histology images.Npj imaging · 2024Article
- Article
- Establishment of cancer-associated fibroblasts-related subtypes and prognostic index for prostate cancer through single-cell and bulk RNA transcriptome.Scientific reports · 2023Article
- Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients.European journal of medical research · 2023Article
- Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.Journal of cancer research and clinical oncology · 2023Article
- Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients.Journal of translational medicine · 2022Article
- Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based Study.Cancers · 2022Article
- Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer.Computational and mathematical methods in medicine · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Screening for prostate cancer is a controversial topic within the field of urology. The US Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial did not demonstrate any difference in prostate-cancer-related mortality rates between men screened annually rather than on an 'opportunistic' basis. However, in the world's largest trial to date--the European Randomised Study of Screening for Prostate Cancer--screening every 2-4 years was associated with a 21% reduction in prostate-cancer-related mortality rate after 11 years. Citing the uncertain ratio between potential harm and potential benefit, the US Preventive Services Task Force recently recommended against serum PSA screening. Although this ratio has yet to be elucidated, PSA testing--and early tumour detection--is undoubtedly beneficial for some individuals. Instead of adopting a 'one size fits all' approach, physicians are likely to perform personalized risk assessment to minimize the risk of negative consequences, such as anxiety, unnecessary testing and biopsies, overdiagnosis, and overtreatment. The PSA test needs to be combined with other predictive factors or be used in a more thoughtful way to identify men at risk of symptomatic or life-threatening cancer, without overdiagnosing indolent disease. A risk-adapted approach is needed, whereby PSA testing is tailored to individual risk.
Indexed as
Identifiers
23247693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.